20/20 Biolabs Inc (NASDAQ:AIDX) Sees Large Increase in Short Interest

20/20 Biolabs Inc (NASDAQ:AIDX) was the target of a large growth in short interest in June. As of June 15th, there was short interest totaling 291,990 shares, a growth of 126.7% from the May 31st total of 128,775 shares. Based on an average daily trading volume, of 2,692,121 shares, the short-interest ratio is presently 0.1 days. Approximately 2.8% of the shares of the stock are sold short.

20/20 Biolabs Trading Down 4.8%

Shares of 20/20 Biolabs stock traded down $0.03 on Monday, reaching $0.57. The stock had a trading volume of 68,034 shares, compared to its average volume of 658,713. 20/20 Biolabs has a fifty-two week low of $0.54 and a fifty-two week high of $50.00. The business has a 50-day moving average price of $1.13.

20/20 Biolabs (NASDAQ:AIDX) last released its earnings results on Wednesday, May 20th. The company reported ($0.28) EPS for the quarter. The company had revenue of $0.35 million for the quarter.

Analysts Set New Price Targets

A number of brokerages have recently weighed in on AIDX. Maxim Group began coverage on shares of 20/20 Biolabs in a research note on Monday, May 11th. They set a “buy” rating and a $5.00 price objective for the company. Wall Street Zen raised shares of 20/20 Biolabs to a “hold” rating in a research note on Saturday, March 14th. Finally, Weiss Ratings started coverage on 20/20 Biolabs in a report on Thursday, May 14th. They set a “sell (e-)” rating for the company. One equities research analyst has rated the stock with a Buy rating and one has given a Sell rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of “Hold” and a consensus price target of $5.00.

About 20/20 Biolabs

We develop and commercialize AI-powered, laboratory-based blood tests for the early detection and prevention of cancers and chronic diseases. We offer two families of lab tests, both under our OneTest brand: (i) OneTest for Cancer, a multi-cancer early detection, or MCED, blood test which has been our primary commercial focus and source of revenues since we wound down our COVID-19 testing business, and (ii) OneTest for Longevity, which measures inflammatory biomarkers, that we expect to launch in the first half of 2026.